The joint effect of triglyceride-glucose index and C-reactive protein levels on the risk of chronic obstructive pulmonary disease: a prospective cohort study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2002-

C-Reactive Protein*/metabolism ; C-Reactive Protein*/analysis ; Pulmonary Disease, Chronic Obstructive*/blood ; Pulmonary Disease, Chronic Obstructive*/epidemiology ; Triglycerides*/blood ; Blood Glucose*/metabolism ; Blood Glucose*/analysis; Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Aged ; Biomarkers/blood ; Risk Factors ; Proportional Hazards Models ; ROC Curve ; Adult

Competing Interests: Declarations. Ethics approval and consent to participate: The ethics approval was obtained from the North West Multi-Center Research Ethics Committee (06/MRE08/65). The informed consent was provided before investigation. Consent for publication: Not applicable for this study. Competing interests: The authors declare no competing interests.
Background: The triglyceride-glucose index (TyG) and C-reactive protein (CRP) are key biomarkers on clinical diagnosis, each related to lung dysfunction. However, the relationship of both indexes with the risk of chronic obstructive pulmonary disease (COPD) is still unclear. This study purposes to focus on the individual and joint associations of TyG and CRP levels with COPD risk.
Methods: This cohort study utilized baseline TyG and CRP data from the UK Biobank. Hazard ratios (HRs) and 95% confidence intervals (CIs) for COPD risk associated with TyG and CRP levels were calculated through Cox regression models. Receiver operating characteristic (ROC) curves were conducted to determine the optimal cut-off values for TyG and CRP, which were combined into a joint variable. Kaplan-Meier (KM) method was utilized to analyze cumulative hazard, while joint analysis was employed for evaluating the joint risk. Stratified and sensitivity analyses were also performed to assess the associations within subgroups, and mediation effect of TyG on COPD risk via CRP levels was assessed.
Results: This study enrolled 385,523 individuals, with 10,515 COPD cases were recorded in follow-up. Compared to the lowest quintile, individuals with higher TyG and CRP had increased risk of COPD (all HRs > 1.00). The optimal cut-off values of TyG and CRP were 7.14 and 1.88 mg/L, and we found that the simultaneous elevation of both TyG and CRP significantly increased the risk of COPD. Moreover, the joint effect was stronger in participants younger than 60 years old, males, smokers or passive smokers, those with body mass index (BMI) < 25.0 kg/m ² , and those without baseline diabetes, asthma, or a family history of respiratory diseases (P for interaction < 0.05). Moreover, the effect of TyG on COPD was significantly mediated by CRP, explaining almost 15.6% of this influence.
Conclusions: These results underscored the individual and joint effects of TyG and CRP upon COPD risk, indicating their usefulness as biomarkers for early risk assessment.
(© 2025. The Author(s).)

Lancet Respir Med. 2024 Jan;12(1):15-16. (PMID: 38061380)
Curr Med Chem. 2020;27(42):7256-7263. (PMID: 31724496)
Physiol Rev. 2023 Apr 1;103(2):1059-1093. (PMID: 36201635)
Pharmacol Ther. 2014 Feb;141(2):125-39. (PMID: 24076269)
J Allergy Clin Immunol. 2015 Aug;136(2):304-11.e8. (PMID: 25748066)
BMJ Open Respir Res. 2023 Jun;10(1):. (PMID: 37353234)
J Pak Med Assoc. 2022 May;72(5):986-988. (PMID: 35713073)
Eur J Public Health. 2020 Aug 1;30(4):822-827. (PMID: 31951259)
Eur Respir Rev. 2017 Jan 31;26(143):. (PMID: 28143876)
Nutrients. 2023 Jun 19;15(12):. (PMID: 37375712)
Cardiovasc Diabetol. 2023 May 2;22(1):103. (PMID: 37131230)
Diabetes Obes Metab. 2023 Sep;25(9):2575-2585. (PMID: 37248816)
Int J Biochem Cell Biol. 2014 Aug;53:77-88. (PMID: 24853773)
Lancet. 2024 May 18;403(10440):2100-2132. (PMID: 38582094)
Cardiovasc Diabetol. 2024 May 7;23(1):156. (PMID: 38715129)
Diabetes Metab J. 2022 Jan;46(1):15-37. (PMID: 34965646)
J Psychiatr Res. 2022 Nov;155:380-386. (PMID: 36182767)
Front Endocrinol (Lausanne). 2022 Nov 03;13:983160. (PMID: 36407320)
Int J Chron Obstruct Pulmon Dis. 2024 Sep 04;19:2001-2010. (PMID: 39253040)
Respir Res. 2024 Nov 26;25(1):414. (PMID: 39593103)
Br J Sports Med. 2023 Jul;57(14):921-929. (PMID: 36754587)
Sci Rep. 2024 Sep 30;14(1):22699. (PMID: 39349929)
Nutr Metab Cardiovasc Dis. 2023 Jun;33(6):1245-1253. (PMID: 37095018)
Front Immunol. 2020 Feb 11;11:84. (PMID: 32117245)
EBioMedicine. 2022 Aug;82:104154. (PMID: 35816897)
COPD. 2013 Oct;10(5):567-72. (PMID: 23844907)
Front Immunol. 2020 Sep 02;11:1957. (PMID: 32983127)
Chest. 2021 Sep;160(3):1026-1034. (PMID: 33839084)
J Clin Invest. 2006 Jul;116(7):1793-801. (PMID: 16823477)
Int J Chron Obstruct Pulmon Dis. 2022 Jun 17;17:1393-1401. (PMID: 35746923)
Lancet. 2022 Jun 11;399(10342):2227-2242. (PMID: 35533707)
Cardiovasc Diabetol. 2020 Jan 15;19(1):8. (PMID: 31941513)
Front Endocrinol (Lausanne). 2025 Apr 07;16:1534232. (PMID: 40260282)
Mol Aspects Med. 2022 Jun;85:101026. (PMID: 34625291)
Lipids Health Dis. 2024 Jun 22;23(1):190. (PMID: 38909224)
Eur Respir J. 2016 Aug;48(2):403-10. (PMID: 27103388)
BMJ Open Respir Res. 2024 Dec 12;11(1):. (PMID: 39668106)
Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675)
Respirology. 2021 Jun;26(6):532-551. (PMID: 33893708)
Cardiovasc Diabetol. 2025 Mar 08;24(1):108. (PMID: 40057710)
Thorax. 2019 May;74(5):439-446. (PMID: 30617161)
Clin Endocrinol (Oxf). 2016 Jul;85(1):37-45. (PMID: 26708153)
J Epidemiol Glob Health. 2024 Sep;14(3):1332-1340. (PMID: 39225766)

K2023072 the grant from Key Project of Medical Science Research of Jiangsu Provincial Health Commission; H2023022 Jiangsu Provincial Health Commission Medical Research Project Approval

Keywords: C-creative protein; Chronic obstructive pulmonary disease; Joint effect; Triglyceride-glucose index

9007-41-4 (C-Reactive Protein)
0 (Triglycerides)
0 (Blood Glucose)
0 (Biomarkers)

Date Created: 20251007 Date Completed: 20251007 Latest Revision: 20251009

20251009

PMC12502271

10.1186/s12944-025-02732-1

41053749